3rounds
3led
Biotech 3
Series A 1, Series B 1, Series C+ 1
Details
New companies 2 · Follow-on 1
Stages: Series A 1, Series B 1, Series C+ 1
OMass Therapeutics $310M Series CAnaCardio €62.5M Series BBreye Therapeutics €67.5M Series AMost active investors · Sep 16, 2026 – Oct 15, 2026
Ranked by rounds participated in, from announcements in Sep 16, 2026 – Oct 15, 2026. Lead counts include only confirmed lead roles.
Browse by month
3rounds
1led
Biotech 2Agritech 1
Seed 1, Series B 1, Undisclosed 1
Details
New companies 3 · Follow-on 0
Stages: Seed 1, Series B 1, Undisclosed 1
OlsAro €5M SeedAnaCardio €62.5M Series BEnginZyme SEK 75M Equity round3rounds
0led
Biotech 2Agritech 1
Seed 2, Series A 1
Details
New companies 3 · Follow-on 0
Stages: Seed 2, Series A 1
Molagri Undisclosed SeedSensible Biotechnologies $47M Series AWonderTx $125K Seed3rounds
1led
Biotech 3
Series C+ 3
Details
New companies 3 · Follow-on 0
Stages: Series C+ 3
BigHat Biosciences $75M Series CBasecamp Research $140M Series CEnveda $311M Series E2rounds
2led
Biotech 2
Series C+ 2
Details
New companies 2 · Follow-on 0
Stages: Series C+ 2
OMass Therapeutics $310M Series CSling Therapeutics, Inc. $123M Series C2rounds
0led
Biotech 2
Series B 1, Series C+ 1
Details
New companies 2 · Follow-on 0
Stages: Series B 1, Series C+ 1
OMass Therapeutics $310M Series CSoufflé Therapeutics $135M Series B2rounds
2led
Biotech 2
Seed 2
Details
2rounds
0led
Biotech 2
Series B 1, Series C+ 1
Details
New companies 2 · Follow-on 0
Stages: Series B 1, Series C+ 1
Soufflé Therapeutics $135M Series BBigHat Biosciences $75M Series C2rounds
0led
Biotech 2
Seed 2
Details
2rounds
1led
Agritech 1Biotech 1
Series A 1, Series B 1
Details
New companies 2 · Follow-on 0
Stages: Series A 1, Series B 1
Soufflé Therapeutics $135M Series BRobigo Undisclosed Series A2rounds
0led
Biotech 2
Series C+ 1, Undisclosed 1
Details
New companies 2 · Follow-on 0
Stages: Series C+ 1, Undisclosed 1
Boltz Undisclosed Planned strategic investmentBasecamp Research $140M Series C2rounds
0led
Biotech 2
Undisclosed 2
Details
New companies 2 · Follow-on 0
Stages: Undisclosed 2
MOLCURE Undisclosed Strategic investment agreementUnited Immunity ¥2.2B Private financing2rounds
0led
Biotech 2
Series A 1, Series B 1
Details
New companies 2 · Follow-on 0
Stages: Series A 1, Series B 1
AnaCardio €62.5M Series BBreye Therapeutics €67.5M Series A2rounds
1led
Biotech 2
Series A 1, Series B 1
Details
New companies 2 · Follow-on 0
Stages: Series A 1, Series B 1
AnaCardio €62.5M Series BBreye Therapeutics €67.5M Series A2rounds
0led
Biotech 2
Series A 1, Series B 1
Details
New companies 1 · Follow-on 1
Stages: Series A 1, Series B 1
AnaCardio €62.5M Series BBreye Therapeutics €67.5M Series A2rounds
0led
Biotech 2
Series C+ 2
Details
New companies 2 · Follow-on 0
Stages: Series C+ 2
BigHat Biosciences $75M Series CCircle Pharma, Inc. $92.5M Series E2rounds
1led
Biotech 2
Series C+ 2
Details
New companies 2 · Follow-on 0
Stages: Series C+ 2
BigHat Biosciences $75M Series CEnveda $311M Series E2rounds
1led
Biotech 2
Series C+ 2
Details
New companies 2 · Follow-on 0
Stages: Series C+ 2
BigHat Biosciences $75M Series CBasecamp Research $140M Series C2rounds
0led
Biotech 2
Undisclosed 2
Details
New companies 2 · Follow-on 0
Stages: Undisclosed 2
Tempo Therapeutics ≤$2.3M NCI SBIR grantMolecular Targeting Technologies, Inc. $3.2M National Cancer Institute R01 grant2rounds
0led
Biotech 2
Series C+ 2
Details
New companies 2 · Follow-on 0
Stages: Series C+ 2
Basecamp Research $140M Series CEnveda $311M Series E1rounds
1led
Biotech 1
Series C+ 1
Details
1rounds
0led
Biotech 1
Series C+ 1
Details
1rounds
0led
Biotech 1
Series C+ 1
Details
1rounds
0led
Biotech 1
Series C+ 1
Details
1rounds
1led
Biotech 1
Seed 1
Details
1rounds
0led
Biotech 1
Series C+ 1
Details
1rounds
0led
Biotech 1
Series C+ 1
Details
1rounds
0led
Biotech 1
Seed 1
Details
1rounds
0led
Biotech 1
Series C+ 1
Details
1rounds
0led
Biotech 1
Series C+ 1
Details
“—” in Led means every role for that investor in this period is undisclosed; it does not mean zero leads. New companies counts the first participation in a company in our records; follow-on counts later participation.